

Supplementary Appendix 1.

Liou et al. Screening and Eradication of *Helicobacter pylori* for Gastric Cancer

Prevention-The Taipei Global Consensus

This supplement contains the following items:

Table 1S. Grading of Recommendations Assessment, Development and Evaluation (GRADE)

Table 2S. Quality of evidence applied in this consensus report

Table 3S. Updated prevalence of *H. pylori* infection in adults

Table 4S. Randomized controlled trials investigating the risk of GERD after *H. pylori* eradication

Table 1S. Grading of Recommendations Assessment, Development and Evaluation (GRADE)

Step 1	Step 2	Step 3	Step 4	Step 5
A priori ranking	Upgrade/downgrade	Assign final grade	Consider factors affecting recommendation	Make recommendation
High: randomized trial Low: observational study	Down grade for: Risk of bias Inconsistency Indirectness Imprecision Publication bias Upgrade for: Large consistent effect Dose response Confounders only reducing size of effect	High Moderate Low Very low	Balance of desirable and undesirable effects Cost-effectiveness Preference of patients	Strong for using Weak for using Strong against using Weak against using

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328(7454):1490.

Table 2S. Quality of evidence applied in this consensus report

Quality of Evidence	Definition & examples
High	Further research is very unlikely to change our confidence in the estimate of effect. <ul style="list-style-type: none">✧ Several high-quality studies with consistent results✧ In special cases: one large, high-quality multi-centre trial
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <ul style="list-style-type: none">✧ One high-quality study✧ Several studies with some limitations
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate <ul style="list-style-type: none">✧ One or more studies with severe limitations
Very Low	Any estimate of effect is very uncertain. <ul style="list-style-type: none">✧ No direct research evidence✧ One or more studies with very severe limitations✧ Expert opinion

Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328(7454):1490.

Table 3S. Updated prevalence of *H. pylori* infection in adults

Country	Study period	Detection method	HP+	Total	Rate	Journal
Afghanistan	2017	Serology	189	271	69.7%	Asian Pac J Cancer Prev. 2018 Apr 25;19(4):1035-1039.
Afghanistan	2017	Serology	115	152	75.6%	Asian Pac J Cancer Prev. 2017 Nov 26;18(11):3123-3127.
Algeria	2015-2016	PCR	60	107	56.0%	Helicobacter. 2017 Dec;22(6). doi: 10.1111/hel.12446
Argentina		H/CLO	14	23	60.9%	Acta Gastroenterol Latinoam. 2015 Mar;45(1):12-7.
Argentina		UBT/H	87	163	53.4%	World J Gastroenterol. 2018 Jan 21;24(3):397-407
Argentina	2011-2012	PCR	31	61	50.8%	Arq Gastroenterol. 2017 Jul-Sept;54(3):217-221.
Armenia	2017-2018	Serology	90	217	41.5%	Gut Pathog. 2019 Jun 8;11:28.
Australia	2010-2013	HpSA	198	922	21.5%	Helicobacter. 2017 Apr;22(2). doi: 10.1111/hel.12360
Austria	2010-2015	H			2.3%	PLoS One. 2018 May 29;13(5):e0197695.
Azerbaijan	2013-2015	H	103	167	61.7%	Dis Esophagus. 2019 Dec 30;32(11). pii: doz053
Bangladesh	2015	H/RUT/C/Serology	63	133	47.0%	J Infect Dev Ctries. 2018 May 31;12(5):305-312.
Bangladesh	2014	Culture	56	133	42.1%	PLoS One. 2017 Aug 10;12(8):e0182947.
Bangladesh	2015	PCR/RUT	74	111	66.7%	Microbiol Insights. 2016 Nov 17;9:47-50.
Bolivia	2013	serology	143	244	58.6%	Am J Trop Med Hyg. 2018 May;98(5):1275-1280
Brazil	2006-2008	H	324	489	66.3%	Arq Gastroenterol. 2016 Jan-Mar;53(1):49-54.
Brazil			73	113	66.3%	Arq Gastroenterol. 2019 Mar 18. pii: S0004-28032019005001103.
Brazil	2010-2012	H	88	215	40.7%	Arq Bras Cir Dig. 2016;29Suppl 1(Suppl 1):31-34
Brazil	2013-2015	H/RUT	80	163	49.0%	Arq Gastroenterol. 2016 Oct-Dec;53(4):224-227
Brazil	2015-2016	RUT/H	471	1384	34.0%	Arq Gastroenterol. 2019 May 20;56(1):10-14.
Brazil	2014	H	427	2458	17.4%	Arq Bras Cir Dig. 2016 Jul-Sep;29(3):151-154.
Brazil	2015-2016	H	1459	4606	31.7%	Arq Gastroenterol. 2019 Oct-Dec;56(4):419-424

Brazil	2009-2012	H	852	2406	35.4%	Gastroenterol Res Pract. 2018; 2018: 8454125
Brazil	2013-2015	H	13986	45206	30.9%	Gastroenterology Res. 2017 Feb;10(1):33-41.
Bulgaria		UBT	89	150	59.3%	Diagn Microbiol Infect Dis. 2015 May;82(1):85-6.
Bulgaria		Serology	213	294	72.4%	Gastroenterol Res Pract. 2017;2017:9212143.
Cambodia	2011-2015	H	408	1146	35.6%	JGH Open. 2019 Jun 24;4(1):61-68
Cameroon	2013-2015	Serology	217	500	43.0%	BMC Res Notes. 2018 Aug 3;11(1):559.
Cameroon	2012-2016	Serology	232	451	51.5%	BMC Infect Dis. 2019 Jan 8;19(1):30
Cameroon	2014-2015	H/RUT	59	112	52.7%	Med Sante Trop. 2016 Aug 1;26(3):278-282.
Cameroon	2014	serology	132	205	64.4%	BMC Infect Dis. 2018 Jun 15;18(1):278.
Canada	2011-2012	H	28	159	17.6%	Can Fam Physician. 2016 Sep;62(9):e547-54.
Canada	2010-2017	H	35	200	17.5%	Obes Surg. 2020 Feb 6. doi: 10.1007/s11695-020-04436-0
Canada	2016-2017	Serology	15	71	21.0%	Can Pharm J (Ott). 2020 Feb 18;153(2):101-107
Chile	2015	RUT	538	1862	28.9%	Rev Med Chil. 2018 May;146(5):555-561.
Chile	2018	RUT	104	229	45.4%	Pathogens. 2019 Nov 9;8(4). pii: E226.
Chile	2016	H	123	160	77.0%	Rev Med Chil. 2018 May;146(5):596-602
China	2015-2017	Serology	4155	9571	43.4%	J Gastroenterol. 2019 Sep;54(9):784-791.
China	2016	UBT	645	2051	31.4%	Gastroenterol Res Pract. 2018 Jan 21;2018:8040262.
China	2013-2014	UBT	479	1195	40.1%	BMC Gastroenterol. 2019 Jan 21;19(1):14.
China	2009-2016	H	699	2326	30.0%	World J Gastroenterol. 2017 Nov 21;23(43):7756-7764.
China	2013-2014	UBT	10848	28171	38.5%	Front Microbiol. 2018 Jan 31;9:73.
China	2013	UBT	6614	30810	49.6%	Diabetes Metab Res Rev. 2016 Jan;32(1):95-101.
China	2015	UBT	228	646	35.3%	BMC Infect Dis. 2019 Mar 5;19(1):228.
China	2003-2012	RUT	42187	131930	32.0%	Springerplus. 2016 Sep 19;5(1):1601.

China	2015-2017	H	108	298	36.2%	J Int Med Res. 2019 Feb;47(2):748-753.
China	2013-2014	Serology	4541	22044	20.6%	Int Urol Nephrol. 2017 May;49(5):845-850
China	2014	UBT	3750	10912	34.4%	Turk J Med Sci. 2017 Nov 13;47(5):1456-1462.
China	2011	UBT	105973	183970	57.6%	Gut. 2016 Jan;65(1):9-18.
China	2015-2016	UBT	829	3014	27.5%	Medicine (Baltimore). 2019 Jan;98(2):e14113.
China	2013-2014	UBT	9836	22103	44.5%	Bratisl Lek Listy. 2016;117(9):521-524.
China						J Hum Hypertens. 2018 Feb;32(2):158-164.
China	2016-2017	UBT	2506	4796	52.3%	BMC Gastroenterol. 2019 Nov 14;19(1):186.
China		Serology	2978	10407	28.6%	Sci Rep. 2016 Aug 30;6:32334.
China	2014-2016	UBT/H	828	2003	41.3%	Front Oncol. 2020 Mar 3;10:205.
China	2012-2015	Serology	7803	17971	43.4%	J Gastroenterol Hepatol. 2018 Jun;33(6):1207-1212
China	2014-2016	UBT	845	1641	58.5%	World J Gastroenterol. 2017 Feb 28;23(8):1443-1449.
China	2015	UBT	7848	20384	38.5%	Medicine (Baltimore). 2018 Nov;97(46):e13271
China	2015	UBT	1949	4321	45.1%	Ann Clin Lab Sci. 2017 May;47(3):323-327
China	2013-2016	Serology	16364	51299	31.9%	Turk J Gastroenterol. 2017 Mar;28(2):94-97.
China	2010-2014	UBT	3410	10016	34.0%	World J Gastroenterol. 2015 Aug 7;21(29):8912-9.
China	2014-2016	UBT	2762	5558	49.7%	Helicobacter. 2019 Oct;24(5):e12632
Czech	2010-2011	UBT	367	1195	30.7%	Eur J Gastroenterol Hepatol. 2018 Jan;30(1):76-82.
Denmark	2010-2013	UBT	3556	18940	18.8%	Rheumatol Int. 2020 Mar;40(3):359-366
Denmark	1998-1999	UBT	1007	5749	17.5%	Clin Gastroenterol Hepatol. 2017 Nov;15(11):1715-1723.e7.
Dominica		Culture	64	158	40.5%	Am J Trop Med Hyg. 2017 May;96(5):1050-1059.
Egypt	2013-2014	HpSA	24	108	22.2%	J Infect Dev Ctries. 2017 Jul 31;11(7):577-582
Egypt	2019	HpSA	538	546	83.0%	Diabetes Metab Syndr Obes. 2020 Mar 2;13:619-625

Egypt	2016-2017	RUT/PCR	54	118	45.8%	Int J Microbiol. 2018 Apr 5;2018:4809093.
Estonia	2015-2016	PCR	44	68	64.7%	Int J Mol Sci. 2018 Jan 24;19(2). pii: E338.
Ethiopia	2010-2017		6600	14206	46.5%	BMC Gastroenterol. 2019 Jan 10;19(1):8.
Ethiopia	2016	Serology	143	201	71.1%	Can J Infect Dis Med Microbiol. 2018 Oct 18;2018:9463710
Ethiopia	2016 05-07	serology	207	342	60.5%	BMC Infect Dis. 2018 Jun 7;18(1):260.
Ethiopia	2015-2016.2	serology	255	363	70.2%	Gut Microbes. 2018;9(3):252-263
Ethiopia	2017-2018	HpSA	125	331	37.8%	BMC Infect Dis. 2019 Feb 6;19(1):118.
Ethiopia	2009-2013	Serology	2733	6566	41.6%	Res Rep Trop Med. 2016 Jul 8;7:17-22.
France	2000-2015	H	6873	16764	41.0%	Dig Dis. 2019 Oct 25:1-7.
France	2013	H	44	201	22.0%	Obes Surg. 2018 Dec;28(12):3958-3964
Germany		Serology	149	516	28.9%	Z Gastroenterol. 2017 Jul;55(7):653-656.
Germany	2011-2015	Serology	72	189	38.1%	J Clin Med. 2018 Mar 5;7(3). pii: E44.
Germany	2016-2017	serology	63	254	25.0%	J Gastrointestin Liver Dis. 2018 Jun;27(2):119-125.
Germany	2007	Serology	586	2075	28.2%	Front Public Health. 2019 Apr 24;7:96
Ghana		RUT	39	76	51.3%	BMC Res Notes. 2016 Aug 30;9(1):421.
Ghana	2018	RUT	160	371	44.9%	Pan Afr Med J. 2019 Oct 11;34:82.
Ghana	2010-2012	RUT	34	64	53.1%	Afr Health Sci. 2016 Jun;16(2):611-9
Ghana	2010-2012	CLO	173	231	74.9%	Pan Afr Med J. 2015 Feb 26;20:178.
Ghana	2012	CLO	575	1273	45.2%	Ghana Med J. 2015 Sep;49(3):147-53.
Hungary	2017-2018	Serology	321	1001	32.0%	World J Gastroenterol. 2019 Nov 14;25(42):6365-6372
Hungary	2014	Serology	2385	8107	29.4%	United European Gastroenterol J. 2016 Jun;4(3):388-94.
India	2014	H	10	25	40.0%	Indian J Pathol Microbiol. 2016 Jan-Mar;59(1):66-8.
India		Serology/H/RUT	85	100	85.0%	J Family Med Prim Care. 2018 May-Jun;7(3):577-580

India	2012-2014	RUT	414	1539	27.0%	Indian J Med Res. 2018 May;147(5):517-520.
India	2014-2015	PCR	61	165	37.0%	Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):66-69
India	2012-2014	H	66	120	55.0%	J Clin Diagn Res. 2017 Aug;11(8):VC11-VC15
India	2014-2016	RUT	475	863	55.0%	Environ Sci Pollut Res Int. 2020 Mar;27(8):8580-8585.
India	2012-2013	PCR	22	71	31.0%	J Clin Diagn Res. 2017 Aug;11(8):DC23-DC26.
India	2010-2012	H+CLO	97	165	58.8%	Trop Doct. 2017 Jan;47(1):2-6. Epub 2016 Jan 15.
Indonesia	2015	UBT	29	193	15.0%	Asian Pac J Cancer Prev. 2016 Oct 1;17(10):4747-4753.
Indonesia	2014-2015	H	2	104	1.9%	PLoS One. 2018 Nov 14;13(11):e0205644.
Indonesia	2012-2015	H/culture	88	894	10.4%	PLoS One. 2016 Dec 1;11(12):e0166199.
Indonesia	2015	Serology	20	233	8.6%	PLoS One. 2017 May 2;12(5):e0176203.
Indonesia	2012	culture/H/CLO	7	78	11.5%	Epidemiol Infect. 2015 Apr;143(5):986-96.
Indonesia	2014	Urine test	14	88	15.9%	Biomed Res Int. 2015;2015:152823.
Indonesia	2014-2015	CLO or H or H	59	267	22.1%	PLoS One. 2015 Nov 23;10(11):e0140186.
Iran		Serology	108	200	54.0%	Jpn J Infect Dis. 2017 Nov 22;70(6):672-674.
Iran		Serology	66	97	68.0%	Monoclon Antib Immunodiagn Immunother. 2019 Dec;38(6):277-281.
Iran	2016-2017	RUT	177	305	58.0%	Iran J Neurol. 2019 Jan 5;18(1):19-24
Iran	2008-2014	H	12406	14860	83.5%	Gastroenterol Hepatol Bed Bench. 2015 Spring;8(Suppl 1):S23-9.
Iran	2014-2015	UBT	27	81	33.3%	Middle East J Dig Dis. 2017 Apr;9(2):107-110.
Iran		RUT/PCR	51	105	48.6%	Adv Pharm Bull. 2016 Jun;6(2):261-6.
Iran		Serology	221	497	44.5%	Gastroenterol Hepatol Bed Bench. 2019 Winter;12(1):31-37.
Iran	2012-2013	HpSA	23	100	23.0%	Postepy Dermatol Alergol. 2015 Feb;32(1):15-20.
Iran	2014	Serology	42	130	30.8%	J Med Life. 2019 Apr-Jun;12(2):168-172

Iran	2012-2013	serology	69	103	67.0%	J Family Reprod Health. 2016 Jun;10(2):80-4
Iran		Serology	143	250	57.2%	Acta Med Iran. 2016 Dec;54(12):771-777.
Iran	2016	Serology	84	140	60.0%	Neurol Res. 2017 Nov;39(11):953-958
Iran	2010-2015	Serology	4500	6185	72.8%	Iran J Pathol. 2017 Spring;12(2):183-188
Iran	2014	H	31	50	62.0%	Gastroenterol Hepatol Bed Bench. 2017 Summer;10(3):178-183.
Iran	2015-2016	Serology	33	100	33.0%	Caspian J Intern Med. 2018 Winter;9(1):54-59.
Iraq	2018	HpSA/Serology	132	180	73.3%	Open Access Maced J Med Sci. 2019 Oct 10;7(19):3211-3215
Iraq	2014-2015	Serology	111	161	68.9%	Transplant Proc. 2016 Jan-Feb;48(1):92-5.
Ireland	2013-2014	H or culture	44	123	36.0%	United European Gastroenterol J. 2015 Oct;3(5):432-6.
Israel	2007-2008	serology	1219	1644	74.1%	BMJ Open. 2019 Jan 29;9(1):e024689
Israel	2002-2012	UBT	76935	147936	52.0%	Helicobacter. 2019 Feb;24(1):e12553.
Israel	2013	Serology	48	111	43.2%	Medicine (Baltimore). 2016 Jul;95(29):e4074
Italy	2012-2017	H	228	925	24.7%	Obes Surg. 2018 Jun;28(6):1760-1765
Italy	2005-2014		122	234	52.1%	Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4041-4047.
Italy	2014-2017	UBT/H	132	397	33.0%	Helicobacter. 2018 Apr;23(2):e12465.
Italy	1995-2013	H	4651	9970	46.6%	
Italy	2002-2012	RUT/UBT	1598	5045	31.6%	Helicobacter. 2016 Dec;21(6):575-580.
Italy	2009	Serology	40	136	29.4%	Antibiotics (Basel). 2019 Dec 30;9(1). pii: E12.
Italy	2013-2019	H	175	474	36.9%	Obes Surg. 2020 Apr;30(4):1339-1346
Italy	2014-2015	Serology	32	73	43.8%	Urology. 2017 Feb;100:90-96.
Italy	2015-2016	UBT	686	2922	23.4%	Rev Recent Clin Trials. 2017;12(3):187-192.
Japan	2008-2014	UBT and/or serology	96	255	36.9%	Ther Clin Risk Manag. 2015 Mar 6;11:381-91.

Japan	2009-2013	Serology	90	204	44.1%	PLoS One. 2016 Nov 10;11(11):e0166240.
Japan	2007-2011	Urine Ab tesy	1878	5165	36.4%	Springerplus. 2015 Oct 13;4:602.
Japan	2010-2016	Serology	45	550	8.2%	Intern Med. 2017 Nov 15;56(22):2979-2983.
Jordan	2017-2019	H	257	412	62.4%	Genes (Basel). 2020 Jan 5;11(1). pii: E63.
Jordan	2015-2016	Serology	395	446	88.6%	Helicobacter. 2019 Jun;24(3):e12572
Korea	2009	Serology	2875	5502	52.3%	Korean J Intern Med. 2017 Mar;32(2):309-313.
Korea	2010-2012	H/RUT	529	1140	46.4%	Yonsei Med J. 2016 Nov;57(6):1370-5.
Korea	2012-2013	Serology	3936	6040	65.2%	Int Arch Occup Environ Health. 2016 Aug;89(6):961-6.
Korea	2016-2017	serology	874	1714	51.0%	J Neurogastroenterol Motil. 2018 Oct 1;24(4):603-613.
Korea	2013-2018	H/Culture/RUT	426	1184	36.0%	Helicobacter. 2019 Jun;24(3):e12579.
Korea	2007-2014	RUT	224	463	48.4%	PLoS One. 2018 Mar 2;13(3):e0193646
Korea	2015-2016	serology	2414	4734	51.0%	Helicobacter. 2018 Apr;23(2):e12463
Korea	2010-2014	Serology	1392	2393	58.2%	Dig Dis Sci. 2016 Dec;61(12):3522-3529.
Korea	2013-2015	Serology	210	402	52.2%	Int J Chron Obstruct Pulmon Dis. 2016 Aug 31;11:2055-62.
Korea	2010-2013	Serology	1971	3314	59.5%	Helicobacter. 2015 Feb;20(1):49-55.
Korea	2016-2017	Serology	6569	15196	43.2%	Dig Dis Sci. 2019 Aug;64(8):2219-2230.
Korea	2011	Serology	7288	15994	48.5%	Medicine (Baltimore). 2016 Feb;95(8):e2609
Korea	2016-2017	Serology	1285	2504	51.0%	Scand J Gastroenterol. 2018 Aug;53(8):910-916.
Korea	2007-2009	H	2246	4466	50.2%	Cancer Causes Control. 2017 Feb;28(2):107-115
Korea		H	730	2625	27.8%	Arch Environ Occup Health. 2019 Aug 20:1-6.
Korea	2011-2014	RUT	639	1050	60.9%	Oncotarget. 2017 Jan 24;8(4):6630-6641
Korea	2013-2015	Serology	145	264	55.0%	J Matern Fetal Neonatal Med. 2017 Apr;30(8):995-1000.
Kyrgyzstan				116		Eksp Klin Gastroenterol. 2015;(6):16-20.

Lebanon	2016	H	154	294	52.4%	BMC Gastroenterol. 2018 Apr 16;18(1):48.
Lebanon	2017-2018	H	524	1428	37.0%	BMJ Open Gastroenterol. 2019 Sep 9;6(1):e000330
Lebanon	2015-2016	UBT	476	1030	46.8%	Microb Pathog. 2018 Apr;117:23-26.
Malaysia	2008-2010	Either Proto Dry or H	73	410	17.8%	BMC Gastroenterol. 2015 Aug 12;15:101.
Malaysia		PCR	140	230	60.9%	Br J Biomed Sci. 2016 Oct;73(4):180-187.
Malaysia		Serology	115	257	44.7%	PLoS One. 2016 Jul 21;11(7):e0159830
Mexico	2004	Serology	136	191	71.0%	Nutrients. 2019 Dec 2;11(12). pii: E2922.
Mexico	2015	culture	50	164	30.5%	J Med Microbiol. 2018 Mar;67(3):314-324.
Mexico	2017-2018	HpSA	32	118	27.1%	Clin Rheumatol. 2020 Feb;39(2):463-469
Mexico	2006-2015	H	336	578	58.0%	Rev Gastroenterol Mex. 2016 Jul-Sep;81(3):126-33.
Mexico	2006-2014	PCR	367	767	47.8%	Gut Pathog. 2017 Apr 13;9:18.
Mongolia	2014-2016	H/Culture/RUT	589	736	80.0%	Gut Pathog. 2018 Apr 4;10:14.
Morocco	2015	H/Culture/PCR	177	255	69.4%	Microb Drug Resist. 2017 Sep;23(6):727-732.
Myanmar	2012	CLO/culture/H/serology	121	252	48.0%	World J Gastroenterol. 2015 Jan 14;21(2):629-36.
Nepal	2014	HpSA	4	36	11.1%	BMC Res Notes. 2016 Feb 2;9:59.
Nepal	2016	Serology	792	1918	39.9%	Matern Child Nutr. 2020 Mar 10:e12953
Nepal	2014-2015	H	27	113	23.9%	J Family Med Prim Care. 2019 Mar;8(3):1227-1231
Nepal	2012	H	55	146	37.7%	BMC Microbiol. 2016 Nov 4;16(1):256
Nepal	2013	Serology	64	146	43.8%	Asian Pac J Cancer Prev. 2015;16(17):7911-6.
Nepal	2013	Serology	49	80	61.3%	Asian Pac J Cancer Prev. 2015;16(17):7911-6.
Netherlands	2011-2014	Serology	135	792	17.0%	Helicobacter. 2020 Mar 9:e12687
Netherlands	2008-2013	H/C/S/RUT	42	204	20.6%	Int J Colorectal Dis. 2016 Mar;31(3):693-7.

Nigeria		HpSA	31	200	15.5%	Niger J Clin Pract. 2017 Feb;20(2):188-193.
Nigeria	2014-2017	H	40	104	38.5%	Niger J Clin Pract. 2018 Mar;21(3):375-379
Nigeria	2016-2017	UBT	232	471	49.3%	Minerva Gastroenterol Dietol. 2019 Mar;65(1):36-41.
Egypt	2014	HpSA	143	206	69.4%	J Egypt Soc Parasitol. 2015 Apr;45(1):101-6.
Norway	2004-2005	HpSA	mail	mail	mail	Helicobacter. 2016 Dec;21(6):586-595.
Pakistan		Culture/PCR	37	80	46.3%	Jundishapur J Microbiol. 2016 Jul 3;9(7):e31824.
Pakistan	2015-2016	UBT	399	698	57.0%	J Infect Dev Ctries. 2018 May 31;12(5):342-346
Peru	2018-2018	H	268	633	42.3%	Rev Gastroenterol Peru. 2019 Jul-Sep;39(3):211-214.
Peru	2015-2018	PCR	112	165	62.9%	J Glob Oncol. 2019 Sep;5:1-9.
Peru	2010-2013	UBT	779	1711	45.5%	Rev Gastroenterol Peru. 2016 Jan-Mar;36(1):49-55.
Peru	2013-2014	H	326	573	57.0%	Endosc Int Open. 2016 Oct;4(10):E1083-E1089.
Peru	2014	UBT	80	155	51.6%	Rev Gastroenterol Peru. 2018 Apr-Jun;38(2):138-143.
Poland	2015	UBT	53	148	35.8%	Prz Gastroenterol. 2017;12(2):135-139
Portugal	2016	UBT	81	166	48.8%	Biomed Res Int. 2017;2017:9082716
Puerto Rico	2005-2008	Serology	174	528	33.0%	Helicobacter. 2018 Feb;23(1)
Qatar	2011-2014	H	66	168	39.3%	Obes Surg. 2017 Jul;27(7):1741-1749.
Romania	2014-2015	Serology	41	70	58.6%	Rom J Morphol Embryol. 2016;57(4):1303-1311
Romania	2010-2014	H	63	159	39.6%	Gastroenterol Res Pract. 2016;2016:7230626.
Romania	2010-2014	H/Serology	971	1525	64.0%	Rom J Morphol Embryol. 2017;58(3):809-815
Russia	2013-2015	Serology	704	918	76.7%	Anticancer Res. 2016 Aug;36(8):4129-38
Russia		RUT/Serology	2744	3149	87.1%	Helicobacter. 2017 Feb;22(1). doi: 10.1111/hel.12322
Russia		Serology	422	655	64.4%	Ter Arkh. 2018 Apr 19;90(4):17-20.
Italy	2010-2013	H+CLO or UBT	782	3065	25.5%	Intern Emerg Med. 2015 Oct;10(7):787-94.

Saudi Arabia	2014-2016	PCR	188	404	46.5%	Electron Physician. 2018 Sep 9;10(9):7279-7286
Saudi Arabia	2016-2017		73	302	24.2%	Electron Physician. 2017 Nov 25;9(11):5740-5745
Saudi Arabia	2014-2016	H	146	356	41.0%	Saudi J Gastroenterol. 2020 Jan-Feb;26(1):32-38
Saudi Arabia	2018	HpSA	42	411	10.2%	J Family Med Prim Care. 2019 Jul;8(7):2202-2206.
Saudi Arabia	2017-2018	HpSA	112	421	26.6%	J Family Community Med. 2020 Jan-Apr;27(1):8-14.
Saudi Arabia	2013-2014	H	169	340	49.7%	nt J Environ Res Public Health. 2018 Nov 19;15(11). pii: E2586.
Sénégal	2016	H	61	100	61.0%	Med Sante Trop. 2017 Nov 1;27(4):439-442.
South Africa		Serology	52	92	56.5%	S Afr J Surg. 2015 Dec;53(3 and 4):23-25.
South Africa	2017-2018	PCR	234	444	52.7%	BMC Gastroenterol. 2019 May 14;19(1):73.
South Korea	2006-2017	H/RUT	1027	1463	74.1%	Gut Liver. 2019 Sep 20. doi: 10.5009/gnl19091.
Spain	2009-2013	Serology	111	243	45.0%	Nutr Hosp. 2015 Aug 1;32(2):600-5.
Spain	2017-2018	H	43	140	31.0%	Gastrointest Endosc. 2019 Sep;90(3):461-466.
Spain	2010-2014	H	289	416	69.5%	PLoS One. 2016 Nov 28;11(11):e0166741.
Spain		UBT/HpSA/Serology	38	105	36.2%	Med Oral Patol Oral Cir Bucal. 2016 Sep 1;21(5):e573-8
Spain	2008-2013	Serology	2227	2555	87.2%	Eur J Cancer Prev. 2019 Jul;28(4):294-303.
Spain	2016	H	137	347	39.0%	Gastroenterol Hepatol. 2019 Oct;42(8):476-485.
Spain		H	108	217	49.8%	Helicobacter. 2017 Dec;22(6).
Sudan	2017-2018	Serology	109	166	65.7%	BMC Res Notes. 2018 Jul 28;11(1):517
Sudan	2014-2015	Serology	132	186	71.0%	Clin Pract. 2017 Jun 7;7(3):958
Sweden	2012	Serology	61	388	15.8%	United European Gastroenterol J. 2016 Oct;4(5):686-696.
Taiwan	2016-2017	UBT	41	189	21.2%	J Gastroenterol Hepatol. 2020 Feb;35(2):233-240.
Taiwan	2008-2013	UBT	724	3578	20.2%	Helicobacter. 2015 Jun;20(3):184-91.
Taiwan	2018	UBT/HpSA	78	347	22.5%	J Formos Med Assoc. 2020 Jan 8. pii: S0929-6646(19)31146-5.

Taiwan	2006-2015	RUT	892	2361	37.8%	Oncotarget. 2017 Oct 26;8(65):108655-108664
Taiwan		H	48	148	32.4%	Helicobacter. 2019 Jun;24(3):e12578
Taiwan	2013	RUT	381	867	43.9%	BMC Gastroenterol. 2018 Apr 24;18(1):54.
Taiwan	2012	At least 2 of H/CLO/UBT	21	104	20.0%	J Chin Med Assoc. 2015 Feb;78(2):96-100.
Tanzania	2014	Serology	79	202	39.1%	Afr Health Sci. 2016 Sep;16(3):684-689.
Thailand	2012-2013	UBT/H/Culture	29	94	31.0%	Asian Pac J Cancer Prev. 2019 May 25;20(5):1525-1529
Thailand	2013-2018	UBT	73	257	28.4%	JGH Open. 2019 Jun 24;4(1):49-53.
Thailand	2015-2016	H/Culture	93	273	34.1%	PLoS One. 2017 Oct 30;12(10):e0187113
Thailand	2014-2015	H/PCR	150	300	50.0%	Gastroenterol Res Pract. 2016;2016:9130602.
Thailand	2008-2013	H	710	1546	45.9%	PLoS One. 2015 Sep 10;10(9):e0136775.
Thailand	2016	RUT/culture	53	148	35.8%	Asian Pac J Cancer Prev. 2017 Feb 1;18(2):455-458
Thailand	2014-2015	PCR (stool and saliva)	70	110	64.0%	BMC Microbiol. 2018 Jan 30;18(1):10.
Turkey						Eur Arch Otorhinolaryngol. 2020 Jan;277(1):141-145
Turkey	2017-2018	H/RUT	211	1000	21.1%	J Infect Dev Ctries. 2020 Mar 31;14(3):298-303
Turkey		H	91	320	28.4%	Turk J Med Sci. 2017 Jun 12;47(3):916-922.
Turkey	2014	Serology	138	240	57.5%	Prz Gastroenterol. 2017;12(1):49-54
Turkey	2010-2011	Culture/PCR	84	129	64.0%	J Infect Dev Ctries. 2016 Nov 24;10(11):1177-1182.
Turkey		UBT	647	854	75.8%	World J Gastroenterol. 2017 Jan 21;23(3):525-532.
Turkey	2006-2011	RUT/H	164	234	70.1%	J Pathol Clin Res. 2016 Nov 26;3(1):29-37
Turkey		H	126	291	43.3%	Eur Rev Med Pharmacol Sci. 2017 Dec;21(23):5430-5436.
Turkey		H	99	200	49.5%	Turk J Gastroenterol. 2015 Nov;26(6):468-73.
Turkey	2014-2017	H	103	161	64.0%	Obes Surg. 2018 Oct;28(10):3136-3141.

Turkey	2014	H	95	198	47.9%	North Clin Istanbul. 2017 May 10;4(1):13-21
Turkey	2014-2015	H	150	460	33.0%	Turk J Gastroenterol. 2018 Jul;29(4):379-383.
Turkey		H	13	39	33.3%	Ann Endocrinol (Paris). 2019 Sep;80(4):196-201
Turkey	2011-2012	CLO	118	209	56.5%	Clinics (Sao Paulo). 2015 Jan;70(1):69-72.
Turkey		H	163	195	83.6%	Mikrobiyol Bul. 2019 Jul;53(3):262-273
Turkey	2015	serology	43	81	53.1%	J Obstet Gynaecol Res. 2016 Dec;42(12):1768-1772.
Turkey						Obes Surg. 2019 Nov;29(11):3674-3679
Turkey	2011-2012	H	316	592	53.4%	Euroasian J Hepatogastroenterol. 2016 Jul-Dec;6(2):103-105
Turkey		Culture	82	214	38.3%	Can J Gastroenterol Hepatol. 2019 Jun 13;2019:1271872
Uganda		CLO/H	133	176	75.6%	Afr Health Sci. 2015 Sep;15(3):959-66.
Uganda	2012-2013	PCR	31	122	22.0%	Biomed Res Int. 2017;2017:5430723.
Uganda	2014	H	40	111	36.0%	BMC Res Notes. 2015 Jun 23;8:256.
UK	2005-2013	H	6	33	18.2%	Pancreatology. 2017 May - Jun;17(3):395-402.
United Arab Emirates	2017-2018	HpSA	144	350	41.0%	Pathogens. 2019 Apr 1;8(2). pii: E44.
USA	2008-2013	H	68	400	17.0%	Bariatric Surg Pract Patient Care. 2015 Mar 1;10(1):15-18.
USA	1999-2014	H	2759	14049	19.6%	Gastrointest Endosc. 2020 Jan;91(1):70-77.e1.
USA	2000-2015	H	152086	1130663	13.7%	Clin Exp Gastroenterol. 2018 Jan 18;11:39-49
USA	2006-2016	H	605	4032	15.0%	Indian J Gastroenterol. 2018 May;37(3):235-242.
USA	2010-2014	H	74649	731193	10.2%	Helicobacter. 2016 Dec;21(6):581-585.
USA	2013-2014	Serology	56	284	19.7%	Am J Mens Health. 2017 Jul;11(4):1039-1045.
USA	1999-2000	Serology	464	1005	33.3%	Epidemiol Infect. 2020 Feb 5;148:e20
USA	2012-2013	UBT	49	210	23.0%	Ann Emerg Med. 2015 Aug;66(2):131-9.

USA	2008-2012	Culture or H	347	1200	28.9%	Helicobacter. 2015 Aug;20(4):305-15.
USA	2017-2018	H/RUT/culture/HpSA	19	112	17.0%	Biomed Res Int. 2020 Mar 19;2020:7189519.
USA	2008-2017	H	12	260	4.6%	Obes Surg. 2020 Feb;30(2):657-663.
USA	2015	H	23	326	7.0%	Hum Pathol. 2016 Dec;58:90-96.
USA	2009-2018	H	131758	1289461	10.2%	Am J Gastroenterol. 2020 Feb;115(2):244-250
Venezuela		Serology	133	151	88.1%	Indian J Gastroenterol. 2016 Mar;35(2):106-12
Vietnam	2012-2013	Serology/RUT/H	188	494	38.1%	Int J Mol Sci. 2018 Mar 1;19(3). pii: E708.
Zimbabwe	2014	Serology	203	300	67.7%	Ann Med Surg (Lond). 2018 Sep 28;35:153-157

Table 4S. Randomized controlled trials investigating the risk of GERD after *H. pylori* eradication

Author	Study population	Study type	Results	References
Bytzer et al.	276 patients with DU	RCT (double-blind) <ul style="list-style-type: none"> Eradication group: <i>n</i> = 139 Placebo group: <i>n</i> = 137 	Eradication therapy did not increase the risk of developing reflux symptoms in DU patients.	Scand J Gastroenterol 2000; 35:1023-32
Vakil et al.	242 patients with DU	RCT (double-blind) <ul style="list-style-type: none"> Cured <i>H. pylori</i> infection: <i>n</i> = 64 Persistent <i>H. pylori</i> infection: <i>n</i> = 178 	The incidence of GERD was not increased in patients who had successful eradication of <i>H. pylori</i> .	Aliment Pharmacol Ther 2000; 14:45-51
Laine et al.	1185 patients with DU	Post hoc analysis of double-blind RCTs <ul style="list-style-type: none"> Cured <i>H. pylori</i> infection: <i>n</i> = 641 Persistent <i>H. pylori</i> infection: <i>n</i> = 544 	<i>H. pylori</i> eradication in patients with DU disease did not lead to the development of erosive esophagitis or the development of new symptomatic GERD.	Am J Gastroenterol 2002; 97:2992-7
Harvey et al.	1558 <i>H. pylori</i> -infected subjects	RCT (double-blind) <ul style="list-style-type: none"> Eradication group: <i>n</i> = 787 Control group: <i>n</i> = 771 	Eradication therapy had no effects on the prevalence of heartburn or reflux between patients receiving eradication therapy and placebo.	BMJ 2004; 328:1417
Ott et al. (Brazil)	147 patients with functional dyspepsia	RCT (single-blind) <ul style="list-style-type: none"> Eradication group: <i>n</i> = 82 Control group: <i>n</i> = 75 	<i>H. pylori</i> eradication did not cause reflux esophagitis in functional dyspeptic patients.	Aliment Pharmacol Ther 2005; 21:1231-9